

CLINAM

European Foundation for
Clinical Nanomedicine

CLINAM 7/ 2014



7th Conference and Exhibition, June 23-25, 2014

Supported by the Swiss Confederation, Swiss Department of Economic Affairs, Education and Research

The European Summit for Clinical Nanomedicine and Targeted Medicine

“Paving the Way to Personalized Diagnostics & Therapy”

**Final Programme, Call for Posters, Call for Exhibitors
Last Update before Summit**

Previous Events on Sunday, June 22, 2014 • General Assembly of the European Society for Nanomedicine (15.30 h) • Meeting of the International Society for Nanomedicine (16.30 h) • Editorial Board Meeting of the European Journal of Nanomedicine (18.00 h – 19.00 h) [All meetings Hall Osaka/Samarkand]
• **Welcome Dinner for Speakers & invited Guests** [19.45 Swissôtel Le Plaza*****, 1st Floor]

Introduction

The **European Foundation for Clinical Nanomedicine (CLINAM)**, the **European Society for Nanomedicine** and the **European Technology Platform on Nanomedicine (ETPN)** invite you to participate in **CLINAM 7/ 2014**, the 7th European Summit for Clinical Nanomedicine and Targeted Medicine. The now indispensable worldwide platform brings together Clinical Nanomedicine and Targeted Medicine into the generic context with Personalized Medicine and offers the international debate on precise, highly effective novel medicine using Nanomedicine and Targeted Delivery for Diagnosis and Therapy, leading to individualized therapy. The translation process from research findings to applications in Nano-medicine and Targeted Medicine has gained significant momentum. The progress to the “medicine of the future” and towards individualized medicine is underway. CLINAM 7/ 2014 is the place to push the borders of the state of the art. In the past decades, biotechnology, systems biology and nanomedicine have developed in separate tracks, but it is increasingly evident that their combination is of particular benefit to clinical medicine: We see the rapidly growing context of a whole set of technologies and applications belonging together in order to develop medicine that originates at the molecular, nanoscale and cellular level and will eventually lead to personalized medicine, customized on patient groups and ultimately individuals via molecular profiling. Two Regulatory Authorities Sessions are part of the Summit. **The Communities from Academia, Government, Health Economy and Industry are called to Participate in this Summit.**

Mandatory Online Registration for Everybody, thus for All:

- Participants • Speakers • Poster Submitters • Exhibitors
- University Village Members • Guests • SNF-Event Participants

We do not accept written or scanned registrations.

Venue: Congress Center Basel, Switzerland Phone +41 58 206 28 28 Fax +41 58 206 2186 info@congress.ch

Contents of Present Folder

Programme Monday, June 23, 2014.....	2
Programme Tuesday, June 24, 2014.....	7
Participants University Village.....	8
Programme Wednesday, June 25, 2014.....	13
The International Regulators Meeting on Nanotechnology.....	17
Call for Posters.....	21
Call for Exhibitors.....	22
General Information.....	23
Registration-Fees (Registration online only)	23
Accommodation, Organizer's Office, CLINAM Advisory Board.....	24
University Village Representatives.....	25
Exhibitors at CLINAM 7/ 2014.....	26
The Collaborators and the Sponsors.....	28

Scientific Committee of the Summit

Prof. Dr. med. Christoph Alexiou, University Hospital Erlangen (D)

Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL)

Prof. Dr. Gerd Binnig, Founder of Definiens Inc., Nobel Laureate, Munich (D)

Patrick Boisseau, European Technology Platform on Nanomedicine (ETPN), Grenoble (F)

Prof. Dr. med Patrick Hunziker, University Hospital Basel (CH) (Committee Chairman)

Prof. Dr. Claus-Michael Lehr, Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken (D)

Beat Löffler, MA, European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH) (Programme Chief) Prof.

Dr. Jan Mollenhauer, University of Southern Denmark and NanoCAN, Odense (DK)

Dr. Yanay Ofran, Systems Biology & Functional Genomics, Bar Ilan University, Ramat Gan (IL)

Prof. Dr. Marisa Papaluca Amati, European Medicines Agency, London (UK)

Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)

Prof. Dr. med. Janos Szebeni, Bay Zoltan Ltd. and Semmelweis/Miskolc Universities, Budapest (H)

Prof. Dr. Viola Vogel, Laboratory of Applied Mechanobiology, ETH, Zürich (CH)

Joint Collaborators of the Summit for Clinical Nanomedicine and Targeted Medicine

European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH)

European Technology Platform on Nanomedicine (ETPN), Berlin (D)

International Association for Pharmaceutical Technology, Focus Group "Drug Delivery" (APV), Mainz (D)

European Society for Nanomedicine (ESNAM), Basel (CH)

International Society for Nanomedicine (ISNM), Basel (CH)

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken (D)

BioNanoNet Research Association" (BioNanoNet), Graz (A)

EU, Directorate-General for Research & Innovation (RTD), Brussels (B)

European Association for Predictive and Preventive and Personalized Medicine (EPMA), Brussels (B)

European Platform for Photodynamic Medicine (EPPM), Hull (UK)

European Materials Research Society (E-MRS), Strasbourg (F)

This Programme is subject to changes. The Copyright is owned by CLINAM Foundation, Basel, Switzerland; Concept and Programme by Beat Löffler, MA

PROGRAMME

Day 1: Monday June 23, 2014

Monday, Plenum, Hall Montreal

1. Opening (08.30)

08.30 **Opening Address on behalf of the European Foundation for Clinical Nanomedicine**

Beat Löffler, MA, CEO of the European Foundation for Clinical Nanomedicine, Basel (CH)

08.40 **Opening Address on behalf of the European Technology Platform on Nanomedicine**

Patrick Boisseau, Chairman, European Technology Platform for Nanomedicine, Grenoble (F)

- 08.50 **Opening Address of the European Commission**
Dr. Rudolf Strohmeier, Deputy Director General of the DG for Research, Brussels (B)
- 09.00 **Opening Address on behalf of Switzerland**
Dr. Gregor Haefliger, Head of the Department for National Research and Innovation, Swiss State Secretariat for Education and Research, Berne (CH)
- 09.15 **Scientific Introduction: Future Contexts of Clinical Nanomedicine and Targeting Medicine**
Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine, Basel (CH)

Break (09.30 – 10.00)

Monday, Plenum, Hall Montreal

2. Perspectives on Targeting and Implications for Personalized Medicine (10.00)

- Chair **Prof. Dr. Yechezkel Barenholz**, Hebrew University, Hadassah Medical School, Jerusalem (IL)
Opening Keynote Lecture
- 10.00 **The Ubiquitin System and Destruction of Our Own Proteins: From Basic Mechanisms, through Pathogenesis of Human Diseases and onto their Drug Targeting. - Some PM Implications**
Prof. Dr. med. Aaron Ciechanover, Tumor and Vascular Biology Research Center, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Nobel Laureate, Haifa (IL)

Monday, Plenum, Hall Montreal

3. Unsolved Problems and Clinical Challenges in Medicine (10.50)

- Chair **Prof. Dr. med. Patrick Hunziker**, Clinic for Intensive Care, University Hospital Basel (CH)
- 10.50 **Unresolved Issues in Chronic Inflammation**
Prof. Dr. Andy Clark BA, Professor of Inflammation, Biology Centre for Translational Inflammation Research School of Immunity and Infection University of Birmingham, Edgbaston (UK)
- 11.05 **Unresolved Issues in Cancer**
Dr. med. Jens Würthner, PhD FFPM, DipPharmMed, Clinical Program Leader, Oncology Translational Medicine, Novartis, Basel (CH)
- 11.20 **Unresolved Issues in Neurodegenerative Disease**
Prof. Dr. med. François Berger, Director of Unit “Nanomédecine et Cerveau” of INSERM and University Grenoble (F)
- 11.35 **Questions and Debate**

Monday, Plenum, Hall Montreal

4. Challenges in Nanoparticle-Host Interaction (11.50)

- Chair **Prof. Dr. Renato Paro**, Chair ETH Zurich Department of Biosystems Science and Engineering, Basel, Professor of Biosystems, University Basel (CH)
Keynote Lecture
- 11.50 **Where worlds meet: Particle-Immune System Interaction**
Prof. Dr. Gerrit Borchard, Professor Biopharmaceutical Sciences, President of the Swiss Society of Pharmaceutical Sciences, Vice President of the European Federation of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Universities of Geneva and Lausanne (CH)

Monday, Plenum, Hall Montreal

5. Accelerating Nanomedicine Innovations (12.25)

- Chair **Dr. Richard Wooster**, Chief Scientific Officer, Blend Therapeutics, Watertown, MA (USA)
Keynote Lecture
- 12.25 **Nanomedicine in 2014: From Academic Discoveries to Societal Impact**
Prof. Dr. med. Omid Farokhzad, Associate Professor and Director of Laboratory of Nanomedicine and Biomaterials, Harvard Medical School and Brigham and Women's Hospital; Founder of BIND Therapeutics, Selecta Biosciences and Blend Therapeutics, Cambridge, Boston (USA)

Lunch (13.00 – 14.20)

Monday, Parallel Session 1, Hall Montreal

6. Nanomaterial Interactions with and in Biological Systems (14.20)

- Chair: **Prof. Dr. Lajos P. Balogh**, Editor-in-Chief, Nanomedicine, Nanotechnology, Biology and Medicine, Elsevier and Member of the Executive Board, American Society for Nanomedicine, Boston (USA)
- 14.20 **Systems Biology Approaches in Nanosafety Assessment**
Prof. Dr. med. Bengt Fadeel, PhD, Nanosafety & Nanomedicine Laboratory (NNL), Institute of Environmental Medicine (IMM), Karolinska Institutet, Stockholm (S) Including 3 minutes Questions
- 14.35 **Interface between Proteins and Inorganic Nanoparticles**
Prof. Dr. Tanja Weil, Director of the Institute of Organic Chemistry III and Macromolecular Chemistry, Ulm University (D) Including 3 minutes Questions
- 14.50 **Manipulating the Immune System with Nanomaterials: From Toxicity to Therapeutic Intervention**
Prof. Dr. Dan Peer, Head, Laboratory of NanoMedicine, Dept. of Cell Research & Immunology, and Dept. of Materials Science & Engineering, Director of the Leona M. and Harry B. Helmsley Nanotechnology Research Fund Tel Aviv University, Tel-Aviv (IL) Including 3 minutes Questions
- 15.05 **Biological Interactions between Nanoscale Living Organisms and Novel Methods to Investigate them**
Prof. Dr. Kenneth A. Dawson, Professor of Physical Chemistry School of Chemistry & Chemical Biology; Director of the Centre for BioNano Interactions, Dublin (IRL) Including 3 minutes Questions
- 15.20 **Protein-Gold Nanoparticle Adsorption Assay for Prostate Cancer Detection and Diagnosis**
Prof. Dr. Qun Treen Huo, Associate Professor, Graduate Program Coordinator NanoScience Technology Center, Department of Chemistry University of Central Florida, Orlando, FL (USA) Including 3 minutes Questions
- 15.35 **Molecular Manipulation at the Nano-scale for the Development of Novel Drugs, Diagnostics and Biomaterials**
Prof. Dr. Ehud Gazit, Chief Scientist of the Science and Technology Ministry of Israel, Professor at the Department of Molecular Microbiology and Biotechnology, Tel-Aviv (IL) Including 3 minutes Questions
- 15.50 **Complement-mediated Hypersensitivity to Nanomedicines: a New Pan-specific Complement Assay for Animal Models**
Prof. Dr. med. Janos Szebeni, Head Department of Nanomedicine Bay Zoltán Institute of Nanotechnology, Budapest (H) Including 3 minutes Questions
- 16.00 **Biological Functionalities of Polymeric Micelle Systems for Targeting Cancer**
Prof. Dr. Nobuhiro Nishiyama, Professor Polymer Chemistry Division, Chemical Resources Laboratory, Tokyo Institute of Technology, Yokohama (J) Including 3 minutes Questions
- 16.15 **Shrinkage of Pegylated and Non-pegylated Liposomes in Serum**
Joy Wolfram, MS, Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX (USA); CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience & Technology of China, Beijing (RC) Including 3 minutes Questions

Break (16.30– 17.00)

Monday, Parallel Session 2, Hall Singapore

7. ETPN - Enabling the Deployment of Nanomedicine in Europe (14.20)

- Chair: **Patrick Boisseau**, CEA-Léti, Chairman of the Board of the ETPN, Grenoble (F)
- 14.20 During Horizon 2020, the research and development in the nanomedicine domain will increasingly progress from the pre-clinical to the clinical testing stage, consolidating thus the efforts initiated under FP7 and providing European stake-holders with R&I programs, funding schemes and infrastructure for the effective translation of nanomedicines. The ETPN strives for this shift by further providing strategic input to the community and decision makers and by implementing the concepts elaborated within the Platform and in the framework of the NANOMED2020 Coordination and Support Action
- 14:20 **Nanocharacterisation as a First Milestone in Translation**
Dr. Scott E. McNeil, Director, Nanotechnology Characterization Laboratory, National Cancer Institute, Frederick (USA)
- 14:40 **What do Nanomed Entrepreneurs Need for Developing their Business?**
Christopher D.T. Guiffre, J.D., MBA, Senior Vice President and Chief Business Officer of Cerulean, Cambridge (USA)

- 15.00 **Are Clinical Trials of Nanopharmaceuticals Specific?**
Dr. Christine Kubiak, Executive Manager of the European Clinical Research Infrastructures Network (ECRIN), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (F)
- 15.20 **Nanomedicine: Ethical Issues and Societal Expectations**
PD Dr. Johann S. Ach Academic Coordinator, Centre for Advanced Study in Bioethics, University of Münster (D)
- 15:40 **How Focussing on the Patient Transforms Clinical Success into Market Success**
Dr. Tom Crabbe, BSc., Director, External Discovery Solutions, UCB, Slough (UK)
- 16.00 **EU-US Cooperation in Nanomedicine: Routes for a Fair Trade**
Dr. Chris Cannizzaro, Physical Science Officer, National Nanotechnology Initiative NNI, “Global Issues in Nanotechnology” Chair, US Department of State, Washington, DC (USA)
- 16:20 **Wrap Up and Conclusions**
Patrick Boisseau, Chairman of the Board of the ETP Nanomedicine, Grenoble (FR)

Break (16.30 – 17.00)

Monday, Parallel Session 3, Hall Sydney

8. Technologies Enabling Personalized Medicine (14.20)

- Chair **Dr. Klaus-Michael Weltring**, Managing Director, Gesellschaft für Bioanalytik Münster e. V., Münster (D)
- 14.20 **Overview of Analytic and Tools for Clinic - Deep Sequencing**
Prof. Dr. Renato Paro, Chair ETH Zurich Department of Biosystems Science and Engineering, Basel, Professor of Biosystems, University Basel (CH)
- 14.35 **Big Data Versus Small Data Analysis - Towards Personalized Medicine Practice**
Dr. Mira Marcus-Kalish, Senior Research Fellow, International Research Affairs, Tel Aviv University, Tel Aviv (IL)
- 14.50 **The Future of Integration of Multimodal Data from Various Analytics into Clinical Decision-making**
Prof. Dr. med. Giacomo Pongiglione, F.A.C.C., Director, Department of Pediatric Cardiology and Pediatric Cardiac Surgery, Bambino Gesù Children’s Hospital, Rome (I)
- 15.05 **Nanosized Probes for Medical Imaging: Challenges and Opportunities**
Dr. Alessandro Maiocchi, Research Projects Manager, Centro Ricerche Bracco, Bracco Imaging SpA, Colleretto Giacosa, TO (I)
- 15.20 **Bio-relevant In Vitro Release Assay for Liposomal Formulation**
Dr. Andreas Fisch, Fellow Pharmaceutical Development Parenterals, Novartis, Basel (CH)
- 15.35 **Personalized Platinum Nanomedicines for Cancer**
Dr. Richard Wooster, Chief Scientific Officer, Blend Therapeutics, Watertown, MA (USA)
- 15.50 **Questions and Debate**

Break (16.30 – 17.00)

Monday, Parallel Session 4, Hall Rio

9. Innovative Tools and Materials and their Impact on Fundamental Biological Functions – A joint Session of the Deutsche Forschungsgemeinschaft and two Swiss National Research Programmes (14.20)

- Chair **Prof. em. Dr. Peter Gehr**, University of Berne, President of NRP 64, Berne (CH)
Prof. Dr. Louis Schlapbach, President of NRP 62, Berne (CH)
Prof. Dr. rer. nat. Dr. h.c. Reinhard Zellner, University of Duisburg-Essen and Coordinator of SPP1313, Essen (D)
- 14.20 The three Programs, the **Priority Program (SPP1313) of the Deutsche Forschungsgemeinschaft (DFG)** “Biological Responses to Nanoscale Particles” and the **2 National Research Programs (NRP) coordinated by the Swiss National Science Foundation**, NRP 62 “Smart Materials” and NRP 64 “Opportunities and Risks of Nanomaterials” will present some of the most recent data of their research projects. They encompass the impact of nanomaterials on the fundamental biological functions, the development of new intelligent materials and combinations of such with new functions, and the development of tools that maximize the advantages of nanomaterials and minimize their risks for humans and the environment.

Nanocapsules and their Specific Interactions with Cells

Prof. Dr. Katharina Landfester, Max-Planck-Institut für Polymerchemie, Mainz (D)

Uptake of Nanoparticles into Cells and Skin

Prof. Dr. Eckart Rühl, Institut für Physikalische Chemie, Freie Universität Berlin (D)

Peptox-effects of Alloy Nanoparticles on Reproduction

Prof. Dr. Stefan Barcikowski, Technische Chemie, Universität Duisburg-Essen (D)

Nanoencapsulation of Silver-based Antimicrobial Drugs

Jacinthe Gagnon, PhD-student of Prof. Katharina Fromm, University of Fribourg (CH)

Temporal Control of Drug Release from Self-heating Hydrogels

Nassajian Moghadam Mohamadreza, PhD-student of Prof. Dominique Pioletti, EPFL, Lausanne (CH)

Break (16.30 – 17.00)

Monday, Parallel Session 1 - Continuation of above session, Hall Rio

17.00 **Polymeric Nanovesicles Generating Reactive Oxygen Species for Efficient Cancer Therapy**

Patric Baumann, PhD-student of Prof. Wolfgang Meier, University of Basel (CH)

Megaopportunities with a Nanorisk? Intravascular Application of Magnetic Metal Nanoparticles

Dr. Inge Herrmann, Institute of Anaesthesiology, University Hospital Zurich (CH)

Toxicity of Abraded Particles from an Epoxy/carbon Nanotube Composite

MSc ETH Mat Sc/PhD Lukas Schlagenhauf Laboratory for Functional Polymers, Swiss Federal Laboratories for Material Science and Technology, Empa, Dübendorf (CH)

Iron Phosphate Nanoparticles for Food Applications do Not Induce Direct Cytotoxicity in Intestinal Cell Lines

MSc ETH Food Sc/PhD Lea von Moos, Laboratory of Food & Nutrition Toxicology, Department of Health Sciences and Technology, ETH Zurich (CH)

17.55 **Questions and Debate**

Short Break (18.15 – 18.30)

Monday, Parallel Session 2, Hall Singapore

10. When will Future Medicine be Cost Efficient and Socio-Economic? (17.00)

Chair **Dr. Peter Burckhardt**, CEO, EVA The Basel Life Sciences Start-up Agency, Basel (CH)

17.00 **An Economic Perspective on Personalized Medicine**

Prof. Dr. Michael Rossbach, Director of Business Development of the Genome Institute of Singapore (SGP)

17.20 **The Socio-Economic Aspects of Novel Nanomedical Technologies**

Dr. Douglas K. R. Robinson, Managing Director of TEQNODE Limited and Researcher at University Paris-Est, Paris (F); Research fellow at the University of Utrecht - NanoNextNL, Utrecht (NL)

17.35 **Enable processes of co-creation during research and innovation- How can society benefit from nano- technology?**

Sonja Hartl, MSc, Scientific Assistent, BioNanoNet Forschungsgesellschaft mbH, Graz (A)

17.50 **Questions and Debate**

Short Break (18.15 – 18.30)

Monday, Parallel Session 3, Hall Sydney

11. Nanomedicine Solutions in Ophthalmology (17.00)

Chair **Prof. Dr. med. Simo Schwartz, Jr.**, PhD, Nanomedicine Coordinator Molecular Biology and Biochemistry, Research Center for Nanomedicine (CIBBIM), Vall d'Hebron University Hospital Research Institute, Barcelona (E)

17.00 **Nanoparticles for Ocular Therapy**

Dr. Tina T. Wong BSc (Hons), MBBS, FRCOphth, FRCS(Ed), FAMS, PhD, Senior Consultant, Glaucoma Service, Singapore National Eye Centre Singapore (SGP)

17.15 **Integrative Nano-Composites And Regeneration of the Eye (I-CARE)**

Prof. Dr. May Griffith, MBA, Professor of Regenerative Medicine, Director, Integrative Regenerative Medicine Centre, Linköping University, Linköping (S)

17.30 **Molecular Medical Devices to Stabilize and Repair Tissue**

Prof. Dr. Rutledge Ellis-Behnke, Director of the Nanomedicine Translational Think Tank Department of Ophthalmology, Medical Faculty Mannheim, Ruprecht-Karls-University, Heidelberg (D)

17.45 **Questions and Debate**

Short Break (18.15 – 18.30)

Monday, Parallel Session 4, Hall Montreal

12. Therapeutic Antibodies (17.00)

- Chair **Prof. Dr. Gert Storm**, Pharmaceutics Faculty of Science, Dept. of Pharmaceutical Sciences, Utrecht University (NL)
- 17.00 **Antibody Drug Conjugates & Active Targeting - State of the Art**
Iwan Bertholjotti, Global Head of Program Management Chemicals, Lonza Ltd., Visp (CH)
- 17.20 **Hapten-binding Bispecific Antibody Platform for Targeted and Pre-targeted delivery of toxins to tumor cells**
Dr. Ulrich Brinkmann, Ph.D., Senior Principle Scientist, Scientific Director Roche for Pharma Research and Early Development - Large Molecule Research, Penzberg (D)
- 17.40 **Antibody and Bispecific Antibody Targeted Nanoparticles for Selective Cancer Therapy**
Dr. Steve Roffler, Ph.D. Research Fellow Institute of Biomedical Sciences Academia Sinica, Taipei (TW)
- 18.00 **Questions and Debate**

Short Break (18.15 – 18.30)

Monday, Plenum, Hall Montreal

13. Rethinking the Goals of Medicine (18.30)

- Chair **Beat Löffler, MA**, CEO of the European Foundation for Clinical Nanomedicine, Basel (CH)
- 18.30 **The Clocks Ticking Within Our Body**
Prof. Dr. Gottfried Schatz, Prof. em. for Biochemistry, Biozentrum, University of Basel, Basel (CH)

19.15 End of Day 1

- 19.40 **Leaving for the Brokerage Evening Event (in front of Swissôtel Le Plaza)**
Evening Event: Brokerage, Dinner, Cultural Moments (20.00) at Landgasthof Riehen

Day 2: Tuesday June 24, 2014

Tuesday, Plenum, Hall Montreal

14. Pushing the Limits of Nanomedicine and Targeted Medicine (08.00)

- Chair **Dr. Neil P. Desai**, Vice President, Strategic Platforms at Celgene Corporation and Senior Vice President, Global Research & Development, Abraxis BioScience LLC, Los Angeles CA (USA)
- 08.00 **Nanodrugs in the Post-Blockbuster World – Critical FDA Regulatory and Patent Issues**
Dr. Raj Bawa, Adjunct Professor, Rensselaer Polytechnic Institute, Troy, NY and Patent Agent, Bawa Biotech LLC, Ashburn, VA (USA)
- 08.20 **Cognitive Computing Approach: "Watson Oncology"**
David Kerr, Director Watson for Healthcare, IBM Corporation, Armonk, NY (USA)
- 08.40 **The Complementary Approach to Watson – "Definiens Oncology"**
Prof. Dr. Gerd Binnig, Founder of Definiens, Nobel Laureate, Munich (D)
- 09.00 **Peptide-based Nanoparticles for Targeted Delivery of siRNA**
Dr. Patrick Y. Lu, Founder, President and CEO, Sirnaomics, Gaithersburg, MD (USA) and Founder, President, CEO/CSO, Chairman, Nanotides Pharmaceuticals Co. Ltd., Guangzhou International Bio-Island, Guangzhou (RC)
- 09.20 **Synthetic Vaccine Particles for Antigen Specific Immune Tolerance**
Dr. Lloyd Johnston, Ph.D. Chief Operating Officer, Senior VP R&D, Selecta Biosciences Watertown, MA (USA)
- 09.40 **Omics and Sequence-Based Medicine**
Dr. Yang Huanming, Co-founder and Chairman of BGI (Beijing Genomics Institute), Director of BGI College, Chinese Academy of Sciences, Beijing, Shenzhen (PRC)
- 10.00 **Questions and Debate**

Break (10.30 – 11.00)

Tuesday, Parallel Session 1, Hall Montreal

15. Late Breaking and Ongoing Trials 1 (11.00)

- Chair **Prof. Dr. med Christoph Alexiou**, Head Division Experimental Oncology/Nanomedicine, University Hospital Erlangen, Erlangen (D)

- 11.00 **PAMAM Dendrimers as Vectors for the Delivery of sa-RNA in the Treatment of Liver Cancer**
Prof. Dr. Donald Tomalia, Distinguished Visiting Professor, Columbia University, NY, Affiliate Professor, Virginia Commonwealth University, Richmond, Adjunct Professor, University of Pennsylvania, Philadelphia
 CEO/Founder NanoSynthons LLC National Dendrimer & Nanotechnology Center Mt. Pleasant, MI (USA)
- 11.10 **First Questions**
- 11.15 **Albumin Bound Sirolimus Nanoparticles (ABI-009) – Early Clinical Studies**
Dr. Neil P. Desai, Principal Investigator, Aadi LLC, Pacific Palisades, CA (USA)
- 11.25 **First Questions**
- 11.30 **Update on New Clinical Studies with Abraxane**
Dr. Neil P. Desai, Vice President, Strategic Platforms at Celgene Corporation and Senior Vice President, Global Research & Development, Abraxis BioScience LLC, Los Angeles CA (USA)
- 11.40 **First Questions**
- 11.45 **CriPec[®] Docetaxel: Nanomedicine with Sustained Efficacy in Oncology in Late-stage Preclinical Development**
Dr. Cristianne JF Rijcken, PharmD, CEO, Cristal Delivery B.V., Maastricht (NL)
- 11.55 **First Questions**
- 12.00 **In Vivo Application of Cu-64 labeled Up Conversion Nanoparticles**
Prof. Dong Soo Lee MD, PhD, Dept. of Nuclear Medicine, College of Medicine, National University Seoul, Seoul (ROK)
- 12.10 **First Questions**
- 12.15 **Antitumor activity of a BCL2-directed DNAi drug in a Phase II study of patients with relapsed or refractory non-Hodgkin's lymphoma**
Dr. Wendi V. Rodriguez, PhD. CSO and VP, Product Development, ProNAi Therapeutics, Inc., Plymouth, MI (USA)
- 12.25 **First Questions**
- 12.30 **Questions & Debate**

Lunch (13.00 – 14.15)

Tuesday, Parallel Session 2, Hall Singapore

16. ETP Nanomedicine Brokerage and CLINAM Universities "Small Speeches" (11.00)

Chair **Dr. Sc. Nat. Ruth Schmid**, Vice President Marketing, SINTEF Materials and Chemistry, Biotechnology and Nanomedicine, Polymer Particles and Surface Chemistry Trondheim (N) and **Nicolas Gouze**, Project Leader, VDI/VDE Innovation, ETPN, Berlin (D)

11.00 **Brokerage:**

With the launch auf Horizon 2020, the new EU Framework Programme for Research and Innovation, Nanomedicine is gaining a new dimension with the funding of excellent research but also of translational projects with clear clinical applications. The calls expected to be published at fall 2014 will therefore require consortia involving a broad range of stakeholders from academia, industry, clinical investigation centers and end-users. The Brokerage event is the opportunity to briefly present your project ideas and by that, to attract further collaborators to improve or to complete the consortium. The session is organized and chaired by Nicolas Gouze from the ETPN. Presentations shall be no longer than 4 minutes and contain a maximum of 4 slides.

12.00 **Universities Small Speeches**

Posters and Results of Scientists at Universities participating in the University Village 2014 are welcome to submit for a small speech of 4 minutes, serving to highlight the research activities in Nanotechnology / Health. The speeches comprise a maximum of three slides, • Slide 1: general introduction to the topic future and outlook on translation of the work presented in a way that is accessible to the highly interdisciplinary audience • Slide 2: some of the highlights of submitters work and institutions work • Slide 3: The prove, how the work at the university / institute fits into the area of Nanomedicine and Targeted Medicine including showing the future and outlook on translation of the work.

University Village

The following countries are represented within the University Village

- Austria • Denmark • Germany • Hungary • Israel • Italy • Poland • Netherlands • Norway
- Switzerland • United Kingdom

Lunch (13.00 – 14.15)

Tuesday, Parallel Session 3, Hall Sydney

17. Value and Methods of Science (11.00)

- Chair **Dr. Douglas K. R. Robinson**, Managing Director of TEQNODE Limited and Researcher at University Paris-Est, Paris (F); Research fellow at the University of Utrecht - NanoNextNL, Utrecht (NL)
- Scientific publishing is undergoing dynamic changes considering how to carry out life sciences research, determine and disseminate its value, and how to monetize this value. Several articles have recently appeared in well-known journals (Science, Nature, The Economist, etc.) questioning the value and methods of science, especially from Preclinical Animal Models to Clinical Trials. In this session we will summarize these dynamics from the editor's, from the publisher's, and from the researchers' view to provide guidance for the participants.

11.00 Scientific Publishing in Nanomedicine

Prof. Dr. Lajos P. Balogh, Editor-in-Chief, Nanomedicine, Nanotechnology, Biology and Medicine, Elsevier and Member of the Executive Board, American Society for Nanomedicine, Boston (USA)

11.20 First Questions

11.25 Publication Ethics

Dr. med. Karin E. Lason, Managing Editor, European Journal of Nanomedicine, De Gruyter, Berlin (D)

11.45 First Questions

11.50 Overcoming the Translation Gap; Nanomedicines: From Preclinical Animal Models to Clinical Trials

Dr. Theresa Mary Allen, Professor Emeritus, Pharmacology and Oncology, University of Alberta, Edmonton; Co-founder and Strategic Advisor, Center for Drug Research and Development, Vancouver (CDN)

12.10 First Questions

12.15 The Role of IT as Enabler of Translational Nanomedicine

Dr. Michael Hehenberger, Ph.D., Partner, HM NanoMed, Westport CT (USA)

12.35 First Questions

12.40 Questions and Debate

Lunch (13.00 – 14.15)

Tuesday, Parallel Session 4, Hall Rio

18. Regenerative Nanomedicine (11.00)

- Chair **Prof. Dr. Alke Fink**, Adolphe Merkle Institute, University of Fribourg, Marly (CH)

11.00 Artificial Muscles Based on Nanotechnology

Prof. Dr. Bert Müller, Thomas Straumann-Chair for Materials Science in Medicine, University Basel (CH)

11.20 Pro-healing Effects of Silver Nano-Particles in Bone Fractures and Tendon Injuries

Dr. Kenneth Wong, Ph.D, FRCSEd, FHKAM, Clinical Associate Professor, Department of Surgery, The University of Hong Kong (HK)

11.40 Self-assembling Peptide Nanofiber Containing long Motif of Laminin Induces Neural Differentiation, Tubulin Polymerization and Neurogenesis; in-vitro, ex-vivo and in-vivo Studies

Dr. Cand. med. Shima Tavakol, Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran (IR)

12.00 Questions and Debate

Lunch (13.00 – 14.15)

Tuesday, Parallel Session 4 Continuation, Hall Rio

19. Nanomaterials: Cellular Handling and New Cellular Targets

- Chair **Dr. Adriele Prina-Mello**, MSc, NAMDIATREAM - Project Coordination Team and ETPN Characterization and Toxicology working group chair, School of Medicine and CRANN Trinity College, Dublin (IRL)

11.50 Role of Specialized Hepatic Scavenger Cells in Control of Biodistribution of Biologics and Nanopharmaceuticals

Prof. Dr. Bård Smedsrød, Founder and CEO of D'Liver, Professor and Group Leader, Vascular Biology Research Group, University of Tromsø (N)

- 12.00 **Nano-formulated Enzymatic Based Chemoadjuvants**
Dr. Pablo Scodeller, PhD Vascular Mapping Laboratory of Dr. Erkki Ruoslahti, Sanford-Burnham Medical Research Institute, La Jolla CA (USA)
- 12.10 **Bone Morphogenetic Protein 7 loaded Microspheres can Suppress Glioblastoma Initiating Cells in Human Primary Tumor Models**
Prof. Marcos Garcia Fuentes, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) Universidad de Santiago de Compostela (E)
- 12.20 **Improving Drugability of the Neuropeptide VIP: Targeted Drug Delivery to Prostate Cancer Cells**
Prof. Dr. David Pozo Perez, Advanced Therapies in Neuroprotection & Immune Regulation Laboratory, CABIMER, (Andalusian Centre for Molecular Biology and Regenerative Medicine), University of Seville, Sevilla (E)
- 12.30 **Questions and Debate**

Lunch (13.00 – 14.15)

Tuesday, Parallel Session 1, Hall Montreal

20. Cutting-Edge Targeted and Personalized Cancer Nanomedicine (14.15)

- Chair **Prof. Dr. Jan Mollenhauer**, University of Southern Denmark, Head Molecular Oncology, Odense (DK)
- 14.15 **Personalized Cancer Nanomedicine**
Prof. Dr. med. Simo Schwartz, Jr., PhD, Nanomedicine Coordinator Molecular Biology and Biochemistry, Research Center for Nanomedicine (CIBBIM), Vall d'Hebron University Hospital Research Institute, Barcelona (E)
Including 3 minutes Questions
- 14.35 **Janus Magnetic Liposomes for Cancer Therapy**
Prof. Dr. Alke Fink, Adolphe Merkle Institute, University of Fribourg, Marly (CH) Including 3 minutes Questions
- Polysaccharide Nanoparticles for Anticancer Drug Delivery**
14.55 **Prof. Dr. Tomasz Ciach**, Warsaw University of Technology, Faculty of Chemical and Process Engineering, Biomedical Engineering Laboratory, Member of the Board of NanoVelos Sp., Warsaw (PL)
Including 3 minutes Questions
- 15.15 **From Genomic Profiles to Personalized Cancer Nanomedicine**
Prof. Dr. Jan Mollenhauer, University of Southern Denmark, Head Molecular Oncology, Odense (DK)
Including 3 minutes Questions
- 15.35 **The Enhanced Permeability and Retention (EPR) Effect and its Relevance to Nanomedicine and Cancer Therapeutics**
Prof. Dr. Alberto A. Gabizon, Hebrew University - School of Medicine - Shaare Zedek MC Oncology Institute, Jerusalem (IL) Including 3 minutes Questions
- 15.55 **Gold Nanoparticles as Carrier for Internalization into Lung Adenocarcinoma Cells: 3 Tiered Approach for Therapeutic Applications**
Dr. Adriale Prina-Mello, MSc, NAMDIATREAM - Project Coordination Team and ETPN Characterization and Toxicology working group chair, School of Medicine and CRANN Trinity College, Dublin (IRL) Including 3 minutes Questions
- 16.15 **Debate**

Break (16.30 – 17.00)

Tuesday, Parallel Session 2, Hall Singapore

21. Neglected Diseases: Diagnostics and Therapy (14.15)

- Chair **Prof. Dr. Reto Brun**, Head Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Basel (CH)
- 14.15 **Neglected Diseases, Current Status and Future Needs**
Prof. Dr. Reto Brun, Head Parasite Chemotherapy, Swiss Tropical and Public Health Institute Basel (CH)
- 14.30 **Multi-pathogen Identification on a Centrifugal Microfluidic Platform – EU FP7 DiscoGnosis**
Dr. Konstantinos Mitsakakis, MSc., Laboratory for MEMS Applications, Department of Microsystems Engineering (IMTEK), University of Freiburg, Freiburg i.Br. (D)
- 14.45 **The Toy Kit Against Malaria: Russian Dolls, Magic Bullets, LEGO, and Trojan horses**
Prof. Dr. Xavier Fernández Busquets, PhD, Nanomalaria Joint Unit, Associate, Institute for Bioengineering of Catalonia, Barcelona, Member of the Barcelona Centre for International Health Research, Barcelona (E)
- 15.00 **Stabilization of viral vectors for vaccines and gene therapy**
Dr. Silke Krol, Fondazione IRCCS Istituto Neurologico "Carlo Besta" IFOM-IEO-campus, Milan (I)

- 15.15 **The Good, The Bad and Ugly: Current Preclinical Nanomedical Strategies Against Dengue and Chagas's Disease**
Prof. Dr. Eder Lilia Romero, Programa de Nanomedicinas, Universidad Nacional de Quilmes, Buenos Aires (AR)
- 15.30 **Therapies in the Developing World with Regard to Access and New Technologies for Delivery**
Prof. Dr. med Matilu Mwau, Associate Professor at the College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya and Chief Research Officer, Centre for Infectious & Parasitic Diseases Control Research (CIPDCR), Kenya Medical Research Institute (KEMRI), Busia (AFR)
- 15.45 **Bioavailability Enhancement of Tafenoquine Antimalarial using Nanoparticle Drug Delivery Systems**
Dr. Paula Melariri, Senior Researcher, Encapsulation & Delivery Research Group Polymers & Composites CSIR Materials Science & Manufacturing The Council for Scientific and Industrial Research (CSIR) in South Africa, Port Elizabeth (ZA)
- 16.00 **Questions and Debate**

Break (16.30 – 17.00)

Tuesday, Parallel Session 3, Hall Sydney

22 .Toxicology in Targeted Medicine and Nanomedicine (14.15)

- Chair **Prof. Dr. med. Janos Szebeni**, Head Department of Nanomedicine Bay Zoltán Institute of Nanotechnology, Budapest (H)
- 14.15 **Investigating the Relationship Between Nanomaterial Toxicology and their Physico-chemical Properties**
Dr. Helinor Johnston, Nano-Safety Research Group, Heriot-Watt University, Edinburgh (UK)
- 14.30 **Toxicology and Safety Prediction**
Prof. Dr. med. Janos Szebeni, Head Department of Nanomedicine Bay Zoltán Institute of Nanotechnology, Budapest (H)
- 14.45 **Comparing Complement Responses between Doxil and Biosimilars**
Prof. Dr. SM Moein Moghimi, Professor of Nanomedicine, Director, Centre for Pharmaceutical Nanotechnology and Nanotoxicology, University of Copenhagen, Copenhagen (DK)
- 15.00 **Immunotoxicity of Nanomedicines - Clinical and Regulatory Aspects**
Prof. Dr. med. Jacques Descotes, PharmD, PhD, fellow ATS, Head, Poison Center and Pharmacovigilance Department Lyon University Hospitals, Lyon (F)
- 15.15 **The Impact of Size and Surface Charge on the Kinetics of Gold Nanoparticles**
Prof. Dr. Wan-Seob Cho, DVM, PhD. Lab of Toxicology, Department of Medicinal Biotechnology, School of Natural Resources and Life Sciences, Dong-A University, Busan (ROK)
- 15.30 **Entry of Nanoparticles into Cells: Mechanisms and Consequences**
Prof. Dr. Kirsten Sandvig, PhD, Centre for Cancer Biomedicine, Oslo University Hospital & University of Oslo (N)
- 15.45 **Biodegradable Versus Non-degradable Nanoparticles: Toxicology and Cost of Development**
Tore Skotland, PhD, Senior Researcher, Centre for Cancer Biomedicine, Oslo University Hospital, Oslo (N)
- 16.00 **Chronic Cytotoxicity: Cellular Effects of Nanoparticle Accumulation**
Prof. Dr. med. Eleonore Fröhlich, Director of Core Facility Microscopy at Center for Medical Research, Medical University of Graz, Member of European Center for Nanotoxicology, Graz (A)
- 16.15 **Questions and Debate**

Break (16.30 – 17.00)

Tuesday, Parallel Session 4, Hall Rio

23. Interaction between Nanomedicines and the Immune System (14.15)

- Chair **Dr. Yanay Ofran**, Systems Biology & Functional Genomics, Bar Ilan University, Ramat Gan (IL)
- 14.15 **Langerhans Cell-targeting DNA Nanomedicine - Clinical Application as Personalized Cancer Vaccines**
Dr. Julianna Lisziewicz, President and CSO, eMMUNITY, Inc. Budapest (H)
- 14.30 **Nanomechanics by Which Macrophages Clear Bacteria**
Prof. Dr. h.c. Viola Vogel, Laboratory of Applied Mechanobiology Department of Health Sciences and Technology ETH Zurich (CH)

- 14.45 **Finding the Balance between Innovation and Bench-to-bedside Translation in HIV Therapy**
Prof. Dr. Alejandro Sosnik, Associate Professor, Department of Materials Science and Engineering of the Technion, Israel Institute of Technology, Haifa (IL)
- 15.00 **Drug Targeting Using Computer-designed Antibody and Antibody Fragments**
Dr. Yanay Ofran, Systems Biology & Functional Genomics, Bar Ilan University, Ramat Gan (IL)
- 15.15 **The Application of Nanotechnology for Optimisation of Antiretroviral Drug Delivery**
Prof. Dr. Andrew Owen, Professor of Pharmacology, Chair of the British Society for Nanomedicine, Molecular and Clinical Pharmacology, University of Liverpool, Liverpool (UK)
- 15.30 **Questions and Debate**

Break (16.30 – 17.00)

Tuesday, Plenum, Hall Montreal

- 17.00 **24. The Regulation Environment in Nanomedicine and Targeted Medicine – Pathway to Individualized Medicine (17.15)**

Chair **Dr. Rudolf Strohmeier**, Deputy Director General of the DG for Research, Brussels (B)

The chance of the CLINAM Summit is that the interdisciplinary community in the field of nanomedicine is present: Also the clinicians and all those, developing findings to products to the benefit of the patient. No group is more important than the global regulatory authorities that seek constantly to globally harmonize the processes of approval of drugs and devices for Nanomedicine and Targeted delivery. From all continents it is the debate between the regulators, the votes of clinicians and the questions of the industrial producers as well as of the members of research institutions that make this session to a fountain of knowledge, experience and can provoke quantum leaps in the future developments of highest scientific and regulatory quality and by mastering of uncertainties to provide for security in advancing the field. It is this joint effort at CLINAM 7/ 2014 that is needed to accelerate the promise that nanomedicine and targeted delivery make to patient and mankind. Every step to minimizing the risk of nanomedicine is a big step forward.

Europe: **Dr. Ana Hidalgo-Simon**, Head of Department Specialised Scientific Disciplines, European Medicines Agency, Human Medicines Evaluation Division, London (UK)

Japan: **Dr. Kumiko Sakai-Kato**, Section Head, Division of Drugs, National Institute of Health Sciences (NIHS), Ministry of Health, Labour and Welfare (MHLW), Tokyo (J)

Canada: **Hripsime Shahbazian, MSc**, Senior Science Advisor, Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa (CND)

China: **Prof. Dr. Guangjun Nie**, Professor of Nanobiology and Nanomedicine, CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, Director of Science and Technology Division, National Center for Nanoscience and Technology of China, Beijing (RC)

USA: **Dr. med. Frank F. Weichold, Ph.D.**, Director of Critical Path and Regulatory Science Initiatives, Office of Regulatory Science & Innovation (ORSI) and Office of the Chief Scientist / Office of the Commissioner Food and Drug Administration (FDA), Silver Spring, MD (USA)

Australia: **Dr. Anne Field**, Senior Toxicologist with the Office of Scientific Evaluation. TGA International Therapeutic Goods Administration, Canberra (AUS)

Africa: **Prof. Dr. med. Matilu Mwau**, Associate Professor at the College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya and Chief Research Officer, Centre for Infectious & Parasitic Diseases Control Research (CIPDCR), Kenya Medical Research Institute (KEMRI), Busia (AFR)

India: **Dr. Sitaramaiah Mokkapati**, Director Research, Kamineni Group, Hyderabad; Former Deputy Director-General in the division of Reproductive Health and Nutrition at Headquarters, Indian Council of Medical Research, New Delhi (IN)

Switzerland: **Lada Leyens, MSc**, GCP Inspector and Clinical Study Reviewer, Division Clinical Trials, Swissmedic, Swiss Agency for Therapeutic Products, Berne (CH)

19.00 End of Day 2

Aperitif at the Poster Sessions and Handing out Poster Awards

The Members of the Poster-award-jury are from Multidisciplinary Fields of Expertise Combining High Level Experience in the Categories Basic Nanomedicine, Translational/Clinical Nanomedicine, and Nanotoxicology.

Day 3: Wednesday June 25, 2014

Wednesday, Parallel Session 1, Hall Montreal

25. Key Characterization Methods for Nanomedicine Applications – Analysis & How to Handle (08.00)

Chair **Prof. Dr. Yechezkel Barenholz**, Hebrew University, Hadassah Medical School, Jerusalem (IL)

There are many types of nano-particulate-based nano-drug formulations including liposomes, polymeric and non-polymeric micelles, sub-micron and nano-emulsions, dendrimers, nano-tubes of various kinds and polymeric drug conjugates. Pegylated and non pegylated nano-particulates are used. While their nano-size enables an EPR effect based passive targeting, all these can also include a desired ligand for active targeting. All nano-drugs are by definition supramolecular assemblies. The experience gained during the last 25 years of nanotechnology and nano-drug development and evaluation demonstrates clearly the need for applying a combination of understanding of the cross talk between physico-chemical, nano-technological, and biological principles. This new session is aimed to give the audience exposure to the main tools used in order to deal with the physicochemical side which is so crucial for the successful development and CMC aspects of nano-drugs.

08.00 **The Essential Role of Physical Chemistry and Biophysics in Nano-drug Development**

Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL)

08.10 **NMR and biophysical methods for the characteriization of novel Lipodisq™ nanoparticles for drug delivery applications**

Prof. Dr. Anthony Watts, Professor of Biochemistry and Fellow of St Hugh's College, Oxford, Director, Biological Solid State NMR Facility at Rutherford Appleton Laboratory, Managing Editor of European Biophysics Journal, Chairman, British Biophysical Society, Oxford (UK)

08.25 **X-ray: Hi-resolution, Structure, Dynamics, and Interactions of Supramolecular Self-assemblies**

Prof. Dr. Uri Raviv, Institute of Chemistry Faculty of Science The Hebrew University of Jerusalem (IL)

08.40 **Electron Microscopy Imaging of Drug Delivery Systems in Liquid State**

Prof. Dr. Oren Regev, Department of Chemical Engineering, Ben-Gurion University of the Negev (IL)

09.55 **Nanomedicine characterization at NCI's Nanotechnology Characterization Lab (NCL): Relating Properties to Performance**

Dr. Scott E. McNeil, Director, Nanotechnology Characterization Laboratory, National Cancer Institute, Frederick (USA)

09.10 **Managing Heat and Disorder, Calorimetric Assays in Life Sciences**

Peter Gimeson, BA, EMEA Application specialist MicroCal at GE Healthcare, Uppsala (S)

09.25 **Short Demonstrations**

09.40 **Questions and Debate**

Break (10.00 – 10.30)

Wednesday, Parallel Session 2, Hall Rio

26. The Challenge of Targeting and Nano-Clinical Application in Cardiology (08.00)

Chair **Prof. Dr. med. Patrick Hunziker**, Intensive Care Unit, University Hospital Basel (CH)

08.00 **Vulnerable Atherosclerotic Plaques – the Significance of Immune-mediated Inflammation / NanoAthero**

Prof. Dr. med. Harald Mangge, Head of the Research Unit on Lifestyle and Inflammation-associated Risk Biomarkers, Vice-Speaker of the Cardiovascular RF Clinical Institute for Medical and Chemical Laboratory Diagnosis, Medical University of Graz (A)

08.15 **Nanotechnologies in Pediatric Cardiology**

Prof. Dr. med. Giacomo Pongiglione, F.A.C.C. Director, Department of Pediatric Cardiology and Pediatric Cardiac Surgery Bambino Gesù Children's Hospital, Rome (I)

- 08.30 **The CosmoPHOS-nano Project**
Dr. med. Panagiotis N. Trohopoulos, Cardiologist, Founder and Scientific / Exploitation / Strategic Coordinator of the EU FP7 NMP Funded CosmoPHOS-nano Project, Executive Board Member of the ETPN, Founder and Managing Director of the CosmoPHOS Ltd, Thessaloniki, Greece (Ellas) (GR)
- 08.45 **Pitfalls and Promises in translating Nanomedical Treatment from Experimental to Clinical Atherosclerosis**
Prof. Dr. med. Erik Stroes, Chair Department of Vascular Medicine, Academic Medical Center (AMC), Amsterdam (NL)
- 09.00 **Extracellular Microvesicles as Potential Biomarkers and Therapeutic Targets in Cardiovascular Disease**
Prof. Dr. Ewa Stepień, Associate Professor in Medical Biology, Collegium Medicum, Faculty of Medicine, Jagiellonian University, Cracow (PL)
- 09.15 **Eradication of Atherosclerosis Synopsis and Outlook**
Prof. Dr. med. Patrick Hunziker, Dep. Head of the Intensive Care Unit, University Hospital Basel (CH)
- 09.30 **Site-specific delivery of chemokine receptor antagonist entrapped in VCAM-1 targeted liposomes attenuate the inflammatory process in atherosclerosis**
Dr. Manuela Calin, Head of Nanotherapy Laboratory and Member of the Scientific Council of the Institute of Cellular Biology and Pathology "Nicolae Simionescu", Bucharest (RO)
- 09.45 **Questions and Debate**

Break (10.00 – 10.30)

Wednesday, Parallel Session 3, Hall Sydney

27. Neurodegenerative Disease: Impacts of BBB in Targeting and Delivery (08.00)

- Chair **Prof. Dr. Giacinto Scoles**, University Hospital, University of Udine, Udine (I) and Biology Department, Temple University, Philadelphia, PA (USA)
- 08.00 **Nanoparticles for Theranostics of Alzheimer Disease**
Prof. Dr. Massimo Masserini, Professor of Biochemistry, Director of the Nanomedicine Center of Milano Bicocca (NANOMIB), Medical School University of Milano-Bicocca (I)
- 08.30 **USPIO-loaded Microbubbles for MR-controlled BBB Permeation**
Dr. Twan Lammers, PhD, DSc, Experimental Molecular Imaging, RWTH Aachen, Aachen (D) and Department of Targeted Therapeutics, University of Twente, Enschede (NL)
- 08.45 **Steroidal Nano-drugs for the Treatment of Multiple Sclerosis**
Moria Barlev-Gross, Research Assistant, Prof. Barenholz group Membrane and Liposome Research, Hadassa Medical School -Hebrew University, Jerusalem (IL)
- 09.00 **Nanoparticles in context to the BBB**
Prof. Dr. med. François Berger, Director of Unit "Nanomédecine et Cerveau" of INSERM and University Grenoble (F)
- 09.15 **Liposomal Nanomedicines to Treat Multiple Sclerosis**
Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)
- 09.30 **Questions and Debate**

Break (10.00 – 10.30)

Wednesday, Parallel Session 4, Hall Singapore

28. Late breaking and ongoing Trials 2 (08.00)

- Chair **Prof Dr.-Ing. Heinrich Hofmann**, Director Powder Technology Laboratory, Institute of Materials EPFL, Lausanne (CH)
- 08.00 **NBTXR3 : Clinical Development and Medical Benefit**
Dr. Rafik Ait Sarkouh, Clinical Research Associate, Nanobiotix S.A., Paris (F)
- 08.20 **Novel Hepatitis B Treatment with RNAi Phase 2**
Dr. Christopher R. Anzalone, Ph.D., President and CEO, Arrowhead Research Corporation Pasadena, CA (USA)
- 08.40 **Implantable siRNA delivery system - treatment for pancreatic cancer Phase 2**
Dr. Amotz Shemi, Chief Executive Officer, Silenseed Ltd, Jerusalem (IL)

09.00 **De Novo Design of Cancer Nanomedicine and Preclinical Progress**
Prof. Dr. Guangjun Nie, Professor of Nanobiology and Nanomedicine, CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, Director of Science and Technology Division, National Center for Nanoscience and Technology of China, Beijing (RC)

09.20 **Questions and Debate**

Break (10.00 – 10.30)

Wednesday, Parallel Session 1, Hall Sydney

29. Novel Applications of Nanophysics to Medical Analytics (10.30)

Chair **Prof. Dr. Hans Joachim Güntherodt**, Honorary President, Swiss Nanoscience Institute (SNI), Basel (CH)

10.30 **Untapped Nonphysical Methods for Diagnosis and Deposited Patent on how to Count and Characterize CTCs**

Prof. Dr. Giacinto Scoles, University Hospital, University of Udine, Udine (I) and Biology Department, Temple University, Philadelphia, PA (USA)

10.40 **Advanced Human in Vitro Models for Off-target Effect Assessment**

Dr. Peter Wick, Co-Head of Materials-Biology Interactions Lab, Empa, Swiss Federal Laboratories for Materials, St. Gallen (CH)

10.50 **Design of Peptides for Functional Magnetic Nanoparticles**

Prof. Dr. Wolfgang Wenzel, Speaker of the Competence Field Nanosciences of the Karlsruhe Institute of Technology (KIT), Karlsruhe (D)

11.00 **Population dynamics of cancer stem cells**

Dr. Stefano Zapperi, Senior researcher at CNR-IENI, Milano (I)

11.10 **A Broad-Spectrum Antiviral Peptide with Highly Discriminate sub 100-nm Membrane Curvature Targeting**

Prof. Dr. Nam-Joon Cho, Deputy Director, Renaissance Engineering Programme (REP) Deputy Director, Nanyang Institute of Technology in Health and Medicine (NITHM) School of Materials Science and Engineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore (SGP)

11.20 **Luminescent Biomaterials for Diagnostic and Therapeutic Applications**

Dr. Gina L. Fiore, Project Leader, Adolphe Merkle Institute, University of Fribourg, Marly (CH)

11.30 **Questions and Debate**

Lunch (12.00 – 13.00)

Wednesday, Parallel Session 2, Hall Singapore

30. A Selection of Materials for Transport in Nanomedicine and Targeted Medicine (10.30)

Chair **Prof. Dr. Witold Lojkowski**, Head of Nanostructures Laboratory, Institute of High Pressure Physics PAS, Polish Academy of Sciences, Warsaw (PL)

10.30 **Microwave Solvothermal Synthesis of Active NanoHA for Medical Applications**

Prof. Dr. Witold Lojkowski, Head of Nanostructures Laboratory, Institute of High Pressure Physics PAS, Polish Academy of Sciences, Warsaw (PL)

10.40 **Targeted Drug Delivery with Magnetic Nanoparticles - The SEON Concept**

Prof. Dr. med Christoph Alexiou, Head Division Experimental Oncology/Nanomedicine, University Hospital Erlangen (D)

10.50 **Liposomes as Drug Delivery System and Vaccination Tool – GMP Manufacturing and Scale up**

Dr. Andreas Wagner, Head Technology, Polymun Scientific, Immunbiologische Forschung GmbH, Klosterneuburg (A)

11.00 **Drug Delivery and Tissue Targeting with Ultra-small Gold Nanoparticles**

Dr. med. Jan Mous, PhD, CEO, PharMida AG, Basel (CH)

11.10 **The Importance of the Composition of the Shell to Influence the in Vivo Behaviour of Inorganic Nanoparticles**

Prof. Dr.-Ing. Heinrich Hofmann, Director Powder Technology Laboratory, Institute of Materials, EPFL, Lausanne (CH)

- 11.20 **Polymer Nanocarriers for Oral Peptide Delivery: the TRANS-INT Concept**
Prof. Dr. María José Alonso, Full Professor of Biopharmaceutics and Pharmaceutical Technology,
University of Santiago de Compostela (USC), Santiago de Compostela (E)
- 11.30 **Questions and Debate**

Lunch (12.00 – 13.00)

Wednesday, Parallel Session 3, Hall Rio

31. Targeted and Functional Nanoparticles for Specific Applications (10.30)

- Chair **Dr. Michael Hehenberger, Ph.D**, Partner, HM NanoMed, Westport CT (USA)
- 10.30 **Magnetic Nanoparticles and Systems for Oncology Care**
Dr. Quentin Harmer, CTO, Endomagnetics Ltd, Cambridge Science Park, Cambridge (UK)
- 10.45 **Cell-specific Targeting to Myofibroblasts: Implications in Cancer and Fibrotic Diseases**
Prof. Dr. Jai Prakash, Assistant Professor, Department of Controlled Drug Delivery, Section Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede (NL)
- 11.00 **Multifunctional nanomedicines for infectious diseases: Enhancing cellular innate immune responses and intracellular drug delivery using nanoparticles**
Dr. Admire Dube, Senior Researcher, Encapsulation & Delivery Research Group Polymers & Composites CSIR Materials Science & Manufacturing, Pretoria (ZA)
- 11.15 **Mucoadhesive Thiochitosan Coated Liposomes for Oral Administration of Drugs**
Prof. Dr. Ruth Prassl, Associate Professor, Institute of Biophysics, Medical University of Graz (A)
- 11.30 **Questions and Debate**

Lunch (12.00 – 13.00)

Wednesday, Parallel Session 4, Hall Montreal

32. European Research Council -Related Talks on Nanomedicine and Drug Delivery Learning about large funded Projects (10.30)

- Chair **Dr. Twan Lammers, PhD, DSc**, Experimental Molecular Imaging, RWTH Aachen, Aachen (D) and Department of Targeted Therapeutics, University of Twente, Enschede (NL)
- Session Keynote Lecture
- 10.30 **SQUALENOYLATION: a Nanomedicine Platform for the Treatment of Severe Diseases**
Prof. Dr. med. Patrick Couvreur, Centre d'études Pharmaceutiques (CNRS), Paris (F)
- 10.55 **SOUNDPHARMA: Image-guided Local Drug Delivery from Nanocarriers Using Focused Ultrasound**
Prof. Dr. Chrit Moonen, Chair of the Image Sciences Institute, University Medical Center Utrecht (NL)
- 11.05 **NEONANO: Neoadjuvant Nanomedicines for Vascular Normalization**
Dr. Twan Lammers, PhD, DSc, Experimental Molecular Imaging, RWTH Aachen, Aachen (D)
- 11.15 **REENGINEERING-CANCER: Re-engineering the Tumor Microenvironment to Alleviate Mechanical Stresses and Improve Chemotherapy**
Dr. Triantafyllos Stylianopoulos, Lecturer of Mechanical Engineering at the University of Cyprus (CY)
- 11.25 **MINDS: Microvesicle-inspired Drug Delivery Systems**
Prof. Dr. Raymond M. Schiffelers, Laboratory of Clinical Chemistry & Hematology, University Medical Center, Utrecht (NL)
- 11.35 **Questions and Debate**

Lunch (12.00 – 13.00)

Wednesday, Parallel Session 5, Hall "Messe Schweiz"- Lounge

33. The International Regulators Meeting on Nanotechnology (10.00 – 12.00)

Part 1 is a Closed Session / Part 2 is an Open Session

Dr. Ana Hidalgo-Simon, Head of Department Specialised Scientific Disciplines, European Medicines Agency Human Medicines Evaluation Division, London (UK)

Dr. med. Frank F. Weichold, Ph.D., Director of Critical Path and Regulatory Science Initiatives, Office of Regulatory Science & Innovation (ORSI) and Office of the Chief Scientist / Office of the Commissioner Food and Drug Administration (FDA), Silver Spring, MD (USA)

Hripsime Shahbazian, MSc, Senior Science Advisor, Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa (CND)

Introduction

The Regulatory Authorities for the evaluation of Nanotechnology enabled products will gather together from various regions of the world within the **CLINAM-Summit** which provides a neutral scientific platform for an open discussion on current regulatory approaches to support nanotechnology applications to the benefit of patients and progress of mankind. Since 2009, the following regulatory authorities have been meeting to discuss nanotechnology: • **Australian Therapeutic Administration** • **European Medicines Agency** • **European Commission** • **European Food Safety Authority** • **Health Canada** • **Japanese Ministry of Health, Labour and Welfare and Pharmaceuticals and Medical Devices Agency** • **United States Food and Drug Administration**

Wednesday, Parallel Session 5, Hall "Messe Schweiz"- Lounge

10:00 Session 1 (CLOSED SESSION, ON WRITTEN INVITATION ONLY)

The International Regulators hold an internal meeting at CLINAM, only open for International Regulatory Members.

It is the opportunity to have an internal face to face discussion and to invite further members of the regulatory authorities by using Internet Web Conferencing. The Agenda of this meeting will be sent out by the organizers directly to the experts. Participants of the CLINAM-Summit are excluded from this session. Potential topics of discussion

- **A process for inviting new members with regulatory authority into the discussion**
- **A joint statement for follow-up debate**

11.15 Session 2 (OPEN TO ALL INTERESTED MEMBERS OF THE CLINAM SUMMIT)

The International Regulators Follow-Up Debate

After the closed meeting the organizers use the neutral scientific CLINAM-Platform to exchange information and to address collaborative approaches of common concern in the field of Nanomedicine All interested participants of the CLINAM Summit are invited to take the chance to communicate together.

Chances

- To hear from the regulatory authorities' members their attempts for harmonization
- Learning about the approach to a global definition of Nanomedicine
- How to improve the transparency to regulated Industry in the future
- Discussing the pathways regarding the medicine of the future.
- Creating personal contacts between stakeholders in Nanomedicine and the regulators since both sides after such meetings know to whom you talk. This creates valuable trust which leads to fruitful results.

Potential Topics

- Current regulatory approach to nanomedicines, nanotechnology-based medical devices and other health Products
- Synergies and gaps across regulatory frameworks (examples of synergies and gaps identified by academia and industry)
- Innovative Regulatory processes to address innovative nanomedicines and available platforms to facilitate the dialogue among industry, academia, scientists and talking to civil society.

Lunch (12.00 – 13.00)

Wednesday, Parallel Session 1, Hall Montreal

34. Nanomedicine and Targeted Drug Delivery: The Pharmaceutical Model towards Novel Medicine (13.00)

This Session is organized jointly with the International Association for Pharmaceutical Technology (APV), Mainz (D)

Chair **Dr. Bernd Riebesehl**, Principal Fellow, Novartis Pharma AG, Basel (CH)

13.00 **EU Horizon 2020 – A Path Towards the Future of Medicine**

Heico Frima, MSc, Programme Officer, EC, Directorate-General for Science & Innovation DG - Industrial Technologies, Brussels (B)

13.15 **In Search of the Magic Bullet: The Future of Drug Targeting and Nanotechnology**

Dr. Riccardo Panicucci, Global Head of Chemical & Pharmaceutical Profiling (CPP), Novartis Institutes for BioMedical Research, Inc., Cambridge, MA (USA)

13.30 **Nanomedinces - An Industry Perspective**

Dr. Marianne Ashford, Principal Scientist, Drug Targeting Medicines Evaluation Pharmaceutical Development AstraZeneca, Cheshire (UK)

13.45 **Noninvasive in Vivo Monitoring of Nanocarriers in Preclinical Models**

Prof. Dr. Karsten Mäder, Martin-Luther-University Halle-Wittenberg, Institute of Pharmacy, Halle (Saale), (D)

14.00 **Bioengineering and Nanotechnology: Preventing Antibiotics Resistant Microbes**

Dr. James L. Hedrick, Research Staff Member, IBM Almaden Research Center, San Jose, CA (USA)

14.15 **Problems and Opportunities to Develop Liposomal Products**

Dr. Peter van Hoogevest, Lipoid GmbH, Ludwigshafen (D)

14.30 **The Unique Tumor Microenvironment in Drug Release**

Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL)

14.45 **Questions and Debate**

Break (15.15 –15.45)

Wednesday, Parallel Session 2, Hall Singapore

35. Cutting-Edge Targeted and Personalized Cancer Nanomedicine 2 (13.00)

Chair **Prof. Dr. Jan Mollenhauer**, University of Southern Denmark, Head Molecular Oncology, Odense (DK)

Session Keynote

13.00 **Combinatorial Development of siRNA Delivery Nano Particles**

Prof. Daniel G. Anderson, PhD, Department of Chemical Engineering, Harvard-MIT Division of Health Sciences & Technology, David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA (USA) Including Questions

13.25 **Lab-on-Chip Devices for Anticancer Drug Activity Evaluation based on Long-term 3D Cell -Culture**

Prof. Dr. Zbigniew Brzozka, Department of Microbioanalytics, Warsaw University of Technology, Warsaw (PL) Including Questions

13.40 **Application of Nanomedicine in Surgery for Thoracic Oncology**

Prof. Dr. med. Hyun Koo Kim, M.D, Ph.D. Department of Thoracic and Cardiovascular Surgery, College of Medicine, University Seoul, Seoul, (ROK) Including Questions

13.55 **Efficient targeting of non-coding RNAs in animal models with LNA antisense oligonucleotides**

Dr. Niels Montano Frandsen, Product Manager, Exiqon A/S, Vedbaek, (DK) Including First Questions

14.10 **Smart Biostable-Aptamer Targeted Nanotherapeutics towards the Treatment of Solid Cancers**

Prof. Dr. Rakesh Naduvil Veedu, Honorary Research Fellow, School of Chemistry and Molecular Biosciences Faculty of Science, University of Queensland (AUS) Including Questions

14.25 **RNAi Therapeutics for the Treatment of Cancer**

Dr. Joshua McCarroll, Project Leader Tumour Biology and Targeting Program, Children's Cancer Institute for Medical Research; Cancer Institute NSW research Fellow. Conjoint Senior Lecturer at the University of New South Wales (AUS) Including Questions

14.40 **Biophysical Markers for Personalization of Nanomedicine-based Tumor Therapy**

Prof. Dr. Biana Godin (Vilentchouk), M.Sc. Pharm., Ph.D., Assistant Professor, Department of Nanomedicine, Houston Methodist Research Institute and Adjunct Assistant Professor, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston (USA) Including First Questions

Break (15.15 – 15.45)

Wednesday, Parallel Session 3, Hall Rio

36. Implications of Nanomedicine: the Ethical View (13.00)

Chair **Dr. Donald Bruce**, Edinethics Ltd., Edinburgh, Scotland (UK)

13.00 **Why do we do Nanomedicine? – An Ethical Case**

Dr. Donald Bruce, Edinethics Ltd., Edinburgh, Scotland (UK)

13.15 **Human Right for Health as Long-term Perspective for Nanomedicine**

Beat Löffler, MA, CEO of the European Foundation for Clinical Nanomedicine, Basel (CH)

13.30 **The Moral Dimensions of Responsibility in Nanomedicine**

Dr. Klaus-Michael Weltring, Managing Director, Gesellschaft für Bioanalytik Münster e. V., Münster (D)

13.45 **Questions and Debate**

Wednesday, Session 3 Continuation , Hall Rio

37. Diagnosis and Therapy Waiting for Nanomedical Solutions (14.15)

Chair **Prof. Dr. Raymond M. Schiffelers**, Laboratory of Clinical Chemistry & Hematology, University, Medical Center, Utrecht (NL)

14.15 **Advanced Particle Analysis: Tunable Resistive Pulse Sensing (TRPS) Clears the Path for Nanomedicine Development and Regulatory Acceptance**

Hans van der Voorn, BE (Hons), CEO, IZON SCIENCE Ltd, Christchurch (NZL)

14.25 **Using Nanoparticle Tracking Analysis (NTA) for Accurate and Complete Nanosuspension Characterisation**

Dr. Bob Carr, Former CTO, Inventor of NanoSight Technology, NanoSight Ltd, Malvern Instruments Ltd, Amesbury, Wiltshire (UK)

14.35 **Empirical Model-based Identification of Critical Quality Attributes in the Precl. Design of Nanostructured Lipid Carriers**

Prof. Dr. Thierry Bastogne, Université de Lorraine, INRIA BIGS, Co-founder of CYBERnano:CRO in Nano Cancerology, Vandoeuvre-lès-Nancy (F)

14.45 **Dynamic Nano-Imaging of Compound Delivery by Multispectral Optoacoustic Tomography (MSOT)**

Dr. Wouter Driessen, iThera Medical GmbH, Munich and a Guest Scientist at the Institute for Biological and Medical Imaging (IBMI) at the Helmholtz Center in Munich, Munich (D)

14.55 **Questions and Debate**

Break (15.15 – 15.45)

Wednesday, Parallel Session 4, Hall Sydney

38. Pharmacokinetics and Physiology in Nanomedicine (13.00)

Chair **Heico Frima, MSc**, Programme Officer, EC, Directorate-General for Science & Innovation DG - Industrial Technologies, Brussels (B)

13.00 **Magnetic Nanoparticle as Intraocular Drug Delivery System to Target Retinal Pigmented Epithelium (RPE)**

Dr. Martina Giannaccini, Institute of Life Science, Scuola Superiore Sant' Anna, Pisa (I)

13.15 **Optimizing Nanomedicine Pharmacokinetics Using Physiologically Based Pharmacokinetics Modelling**

Dr. Marco Siccardi, Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool (UK)

13.30 **Effects of Pegylated Liposomal Nanoparticles on Functionality of Macrophages and Lymphocytes in Tumors**

Prof. Dr. Ninh (Irene) M. La-Beck, Pharm D, Assistant Professor, Department of Immunotherapeutics & Biotechnology, Member and Consultant, ExperImmune-Center for Immunotherapeutic Development, Texas University, Health Sciences Center, Pine St. Abilene TX (USA)

13.45 **Pharmacokinetics Comparison of a Non-Biologic Micellar Paclitaxel Formulation and nab-Paclitaxel - A Case for Bioequivalence**

Dr. Kouros Motamed, VP of Clinical Development & Nanomed, Sorrento Therapeutics Inc., Irvine CA (USA)

14.00 **Questions and Debate**

Wednesday, Parallel Session 4 Continuation , Hall Sydney

39. Nanomedicine in Infection (14.15)

Chair **Prof. Dr. Tomasz Ciach** Warsaw University of Technology, Faculty of Chemical and Process Engineering, Biomedical Engineering Laboratory, Member of the Board of NanoVelos Sp., Warsaw (PL)

- 14.15 **Development of Nanoparticulate Nucleic-Acid based therapeutics, Snares™, for the Treatment of Clostridium Difficile and Prevention of Recurrence**
Kostas Hatzixanthis, Director of Research, Procarta Biosystems Ltd. Procarta Biosystems Ltd, Norwich (UK)
- 14.30 **Ultra-small, Mucus-penetrating Solid Lipid Nanoparticles Enhance the Pulmonary Delivery and Antivirulence of Novel Anti-infectives**
Dr. Noha Nafee Pharmaceutical Technology and Biopharmacy, Philipps-University Marburg, Marburg (D)
- 14.45 **Questions and Debate**

Break (15.15 – 15.45)

Wednesday, Plenum, Hall Montreal

40. The key role of Science leading to Innovation for the benefit of Individuals and Mankind (15.45)

- Chair: **Prof. Dr. Kenneth A. Dawson**, Professor of Physical Chemistry School of Chemistry & Chemical Biology; Director of the Centre for BioNano Interactions, Dublin (IRL)
Beat Löffler, MA, CEO, European Foundation for Nanomedicine, Basel (CH)

This session brings together a number of insights from different viewpoints followed by a discussion. The goal is better insight into scientist's approach to next needs in research and the Innovation Process.

Future

- 15.45 **The Regulatory Approach to Personalized Medicine – Future Rules and Regulations Handling**
Dr. med. Frank F. Weichold, Ph.D., Director of Critical Path and Regulatory Science Initiatives, Office of Regulatory Science & Innovation (ORSI) and Office of the Chief Scientist / Office of the Commissioner Food and Drug Administration (FDA), Silver Spring, MD (USA)
- 16.10 **Questions**
- Innovation**
- 16.15 **Science-based innovations must respect the laws of nature and long-term sustainability**
Prof. Dr. Werner Arber, President, Pontifical Academy of Sciences, Nobel Laureate, Basel (CH)
- Market**
- 16.30 **How to introduce Nanomedicine Products and bring their Impact to the Market**
Dr. Christopher R. Anzalone, Ph.D., President and CEO, Arrowhead Research Corporation Pasadena, CA (USA)
- Data**
- 16.45 **Understanding and Handling Complexity in Medicine - Can Machine Intelligence help?**
Prof. Dr. Gerd Binnig, Founder of Definiens, Nobel Laureate, Munich (D)
- Care**
- 17.00 **Innovation is Driven by Those Who Care and Therefore Find Ways to Change the Status Quo**
Prof. Dr. med. Patrick Hunziker, President of the International Society for Nanomedicine, Basel (CH)
- 17.15 **Debate, Statements and Questions**
- 18.10 **Closing and Announcing CLINAM 8/ 2015**

18.15 End of Day 3 and Summit 2014 (Excursions: Thursday, June 26, 2014)

Light Farewell Dinner for Speakers and Invited Guests Staying in Basel (19.00)

Thursday, June 26, 2014 for those staying in Basel: Excursion to Scientific Institute, Lunch and Visit of Galerie Beyeler in Riehen - a World Famous Art Collection [Separate Registration Mandatory]
<http://www.fondationbeyeler.ch/en/museum/impressions/impressions>

CLINAM SCIENTIFIC MORNING EXCURSION

The Delegates shall visit the ETH Zürich (ETHZ) Department of Biosystems Science and Engineering (D-BSSE) The D-BSSE is one of the ETHZ youngest departments and the only one located in Basel outside of the Zürich campus. The unique blend of researchers working in experimental, theoretical and engineering sciences makes it an exciting venue for academics interested in biological and medical questions.

CLINAM ART AFTERNOON

In the Afternoon the delegates shall visit the unique Art Collection at the Fondation Beyeler. On their web:

“What would a work of art be without people to look at it? Art provokes strong emotions and sets the viewer thinking. An artwork may meet with acceptance or rejection; it may arouse a sense of longing, melancholy, joy, horror, fear, sadness or simply an appreciation of beauty. How art impacts upon the individual viewer is impossible to explain. There are no rules. This is precisely what makes looking at and talking about art with other people so interesting. For art can be commented upon, discussed, loved and celebrated. The Fondation Beyeler is dedicated to communicating art.”

CALL FOR POSTERS

1. Submission Deadlines for Posters

Poster Submission is possible until June 20, 2014. Accepted poster-abstracts arriving **before May 10** will be included in the official Summit-Proceedings. Posters submissions arriving after May 10, 2014 shall not be published in the proceedings. The accepted late submitters are allowed to make handouts **of their poster and bring them to Basel.**

2. Notification on Acceptance or Rejection

You will receive a Decision Form, which tells whether your poster is accepted. **In the case of acceptance you have to confirm your participation within 3 days after receipt.** You must **register online in the registration folder No 5 “Submitted Speakers and Poster Presenters”** at <http://www.clinam.org/conference.html>. Your Registration-Bill has to be paid before the conference and in rare exceptions in cash at the conference desk at arrival.

3. Poster Submissions

Send in one mail all requested 3 Documents to submit2014@clinam.org

Send your poster abstract, (never the full poster!) naming it your **Lastname.Firstname_Submission14. POS. xx** Send your **short CV** (max 1 page, non-tabulated free text) naming it your **LastName.FirstName_CV.xx**. Send your **Portrait Photo** in high resolution (jpg/ gif and not Word!) naming the file to your **LastName.FirstName_Picture.xx** (xx = docx, jpg etc.)

4. Presentation Format

The abstract submission must be written in Microsoft Word, RTF, or Open document file format, NO PDF, using Times New Roman, font size 12, with single spacing and must not be longer than three pages, including metadata and figures (**one figure is obligatory**). All illustrations, figures, and tables are placed within the text at the appropriate points.

5. Contents of Posters

Posters must cover original research aimed at future or current applications of nanoscience and targeted medicine including clinical trial designs, reports of ongoing and completed clinical trials, preclinical work, and technology papers with clinical long-term vision. All fields leading to the development of personalized medicine are also issues of interest.

6. Special Rates for Accepted Submitters

Full Ticket (3 Days)	Regular	ESNAM	Fellowship	Day Ticket (1 Day)	Regular	ESNAM
Submitting Student	€ 460.--	€ 420.--	€ 295.--	Submitting Student	€180.--	€ 160.--
Regular Submitter	€ 610.--	€ 550.--	€ 400.--	Regular Submitter	€ 210.--	€ 190.--

7. Presentation Times and Size of Posters, Installation of Posters

Posters will be located in the Foyer visible for all conference attendees. The meeting breaks and lunches will be the preferred time to study the posters. During lunch and breaks the authors are asked to be present close to their poster. After the sessions of the second day of the conference during the Aperitif some time is dedicated to viewing the posters. Posters are to be presented in **the size of 1.40 meter high and 1.00 meter wide**. There will be the CLINAM-Poster Prize as well as the special poster Award for Nanotoxicology by the European Center for

Nanotoxicology, Graz. **Poster installation is on June 23 as from 06.30 until 8.00 h and can be removed on June 25, 4.30 pm.** The Poster Prizes will be handed out on Tuesday of the Conference after the sessions during the Apéritif.

CALL FOR EXHIBITORS

1. Introduction

The CLINAM 7/ 2014 Summit brings together experts, leaders and decision makers in the fields of Nanomedicine, Targeted Medicine and the development of Personalized Medicine. The exhibition matches the specific interests of participants at the Summit. This Exhibition is dedicated to the pioneers and experts. The CLINAM 7/ 2014 Exhibition will highlight all tools, techniques, developments and research results relating to Nanomedicine, Targeted Medicine and the development of Personalized Medicine in Diagnostics, Drug Delivery, Nanomaterials, Targeting, Related Biotechnology, Nano Systems, Antibody Systems, Simulation Systems. The Foyer Exhibition addresses more than 500 participants of the conference from over 30 countries as the best target public for products, services and consulting cases in a manageable platform presenting all needs in medical targeting, nanomedicine and personalized medicine. This is the opportunity to sell to global pioneers who now are creating and expanding the research and development labs and building up their clinical facilities and is the meeting platform. CLINAM 7/ 2014 is presently best place in the discipline to recruit future employees from among a wealth of skilled experts. The Exhibitors • join the late breaking sessions from all related fields of Nanomedicine and Targeting • profit from bridging between scientists, industry, government leaders, regulatory Authorities and investors • give an oral presentation in the Foyer-Stage or within the conference to explain their products, ideas and cases • present their patents to the conference experts • benefit from networking during the whole event.

2. Exhibition Fees

EXHIBITORS REGISTRATION / EXHIBITORS PACKAGE

The Foyer Exhibition from June 23 to 25, 2014, at the Summit offers an opportunity **to attend at relatively low cost a platform that brings together experts and decision makers in the field at the conference.** It is the ideal place not only to present your exhibits, but also to demonstrate your excellence in the consulting, development and your engagement in this rapidly growing field.

In order to register you have to do this mandatory ONLINE under <https://www.clinam.org/exhibition.html>
Fees of Floor Space, Exhibitors Registration, Evening Event

4 m ² _____	1'200 €
6 m ² _____	1'800 €
8 m ² _____	2'400 € beyond = plus € 270 /
<input type="checkbox"/> Desired segmentation of space: (x by y meter) _____	
<input type="checkbox"/> Company name A3 on pillar _____	80 €
<input type="checkbox"/> 1 table, 2 chairs, 1 pin board for poster & power connection _____	100 €
<input type="checkbox"/> Exhibitors Ticket for Conference (Transferrable) _____	800 €
<input type="checkbox"/> Evening Event Ticket: Your share _____	60 €
<input type="checkbox"/> Industry Visit, City Tour and Museum "Fondation Beyeler" (26.6.) _____	70 €

Need beyond floor space / booth construction including 2 walls, 1 table, 2 chairs, power connection, booth labeling:

4 m ² _____	640 €
6 m ² _____	960 €
8 m ² _____	1'280 € beyond = plus € 160 / m ²

START-UP COMPANY EXHIBITORS REGISTRATION AT LOWER COSTS

Start-up lump-sum booth 4-6 m² including Table, 2 chairs and a pillar with A3 board and 2 movable pin walls cost

- 900 € for 4 or 6 m² of Space
- 300 € for an Exhibitors START UP Conference Ticket (Transferrable; only valid if you will exhibit)
- 60 € for your share in the costs if you participate in the Evening Event on Monday, June 23, 2014

This CLINAM model gives opportunity to participate as young Startup within the CLINAM 7/ 2014 Exhibition. You are a young startup as Entrepreneur or Researcher in the field. You are a startup **company**, a partnership or temporary organization designed to search for a repeatable and scalable **business model**. Your company is newly but not more than 2.5 years created and you are in a phase of **development** and research for **markets**. We ask you in order to be eligible **to profit of this model to write a letter to startup@clinam.org stating** • the field of activity and the goals and the status of the startup • the business case • Date of creation • Personal reason why you attend CLINAM and what you expect from it. • Funding of company (how much; source: private investors, governmental money, research collaboration, other).

3. For further Information

For more general information please contact us by email at Exhib2014@clinam.org European Foundation for Clinical Nanomedicine (CLINAM-Foundation) Alemannengasse 12 P.O. Box, CH-4016 Basel, Switzerland
Phone: + 41 61 695 93 95 Fax +41 61 695 93 90 For registration matters please contact by email clinam2014@insight-outside.fr INSIGHT OUTSIDE 39 chemin du vieux chêne F-38240 Meylan (Grenoble)
Phone: +33 4 38 38 18 18 Fax: +33 4 38 38 18 19

GENERAL INFORMATION ON CLINAM 7/ 2014

1. Target Audience of the Summit

The faculty includes the pioneers and opinion leaders in the fields of medicine, nanoscience and targeted medicine, who share their experience in an interdisciplinary and interactive manner that widens mutual understanding for both sides. The conference and the exhibition are aimed at physicians, as well as nanoscientists with a background in pharmacology, biology, physics, chemistry, biophysics, medicine materials science and engineering. The meeting is a particularly useful source of knowledge for the targeted medicine and delivery community. The Conference is also of interest for policymakers, experts from industry in the field of life sciences, developers of new tools and materials for nanomedicine, and all those investigating the future potential of emerging technologies. Experts from venture companies can acquire knowledge on existing and upcoming developments and novel products in the emerging field of nanomedicine. Government authorities can profit from the regulator's sessions.

2. Registration Fees for the Conference including the Exhibition

Currency is (€)	Ordinary Registration until June 21, 2014			
Type	Regular	ESNAM Members	One Day	One Day ESNAM Member
Academy	650.--	585.--	220.--	200.--
Government	875.--	790.--	300.--	270.--
Industry	1'250.--	1'125.--	450.--	405.--
Student	480.--	430.--	190.--	170.--

3. University Village

As every year in Basel a "University Village" gives ample chances to be updated on the State of the Art at the Universities of Europe and on an international level. Participating in this part of the exhibition is reserved to Universities, Institutes and Research Organizations at a price of **590 Euro** including one transferrable Conference Ticket, Table, Pin Boards and chairs. **Registration is mandatory ONLINE** under Button Number 6 of inscription <https://www.clinam.org/conference.html> and there).

4. “Small Speech” Sessions

Poster presenters and University Village members are eligible for presentations in a special session of Small Speeches, 3 minutes in length and serving to highlight the research activities in Nanotechnology and Targeted Medicine. They must comprise three slides • **Slide 1:** general introduction to the topic • **Slide 2:** some of the highlights of submitters’ work and institutions’ work • **Slide 3:** the proof as to how the work fits into the area of nanomedicine including a glimpse into the future. Application for Small Talk Sessions is possible any time after acceptance of your poster in writing. [Application for Small Speech Sessions is possible any time after acceptance of your Poster.](#) **There are only 30 slots available.** Apply to the University Village Director, **Dr. Ruth Schmid** (ruth.schmid@clinam.org) **before June 10, 2014. Accepted speakers will be notified by June 15, 2014**

5. Credit Points for Continuous Education of MD’s in Switzerland

The European Summit for Clinical Nanomedicine is subject to Credit Points for Switzerland; 24 points approved by the Swiss Medical Association for Clinicians in all fields of Medicine.

6. Nanomed2020 Dissemination-Session

The European Technology Platform on Nanomedicine ETPN, Germany, the European Foundation for Clinical Nanomedicine (CLINAM Foundation), Switzerland, the National Institute of Health Carlos III (ISCIII), Spain, Bioanalytik-muenster e.V (BioMS), Germany, Nanobiotix SA, France, the Fondazione Don Carlo Gnocchi ONLUS (FDG), Italy, and SINTEF Materials and Chemistry, Norway have launched in September 2012 “NANOMED2020”, a one year European project funded by the European Commission under the Work Program FP7-HEALTH-2012. The consortium was created in order to drive innovation in nanomedicine in Europe, by federating its community and structuring the landscape and development of the field for the recently started *Horizon 2020* framework program. The CLINAM-Foundation, as responsible for the *International Relations* activities, has realized with support of this project the 2013 CLINAM conference, and notably the political Sessions of the ETPN, the Session with the Regulatory Authorities (EMA, FDA’s of USA, Canada, Japan, China and Australia) as well as a six hours characterization session under the lead of the Director of the Nanotechnology Characterization Laboratory, National Cancer Institute (USA) and 4 further speakers of this Lab on the Lessons Learned by the US Nanotechnology Characterization Lab (NCL). For the 2014 session, the final results that have been achieved shall be presented by the ETPN, showing how the goal was furthered to make Europe a center for profitable nanomedicine research, development and translation. Furthermore, the Regulatory Authorities will under the Chair of the Directorate General of the DG for Research of the European Commission continue their important debate on the global harmonization of standards.

7. Accommodation

The Swissôtel Le Plaza***** offers for Delegates of CLINAM a special price of CHF 285.— incl. Breakfast
You may reserve your room at the special CLINAM-Rate of CHF 285.—per night including rich breakfast under <https://resweb.passkey.com/go/clinam> Address: Swissôtel Le Plaza Basel Messeplatz 25, CH- 4058 Basel, Switzerland
Phone +41 (0) 61 555 33 33 **For further Hotels in other categories you may contact Basel Tourism that will be pleased to help you in finding accommodation.** Please use the link <http://www.basel.com/en/search/hotels> or contact Basel Tourism, Incoming Services, Tel. +41 (0)61 268 68 58, Fax +41 (0)61 268 68 70 E-Mail incoming@basel.com

Organizers Office of CLINAM 7/ 2014

Please do not hesitate to contact us: European Foundation for Clinical Nanomedicine, Alemannengasse 12
CH 4016 Basel, Switzerland Phone +41 61 695 93 95 E-Mail clinam@clinam.org

The Members of the Advisory Board of the European Foundation for Clinical Nanomedicine

• **Prof. Dr. med. Christoph Alexiou**, Experimental Oncology and Nanomedicine, University Hospital Erlangen (D) • **Prof. Dr. Dr. h.c. Zhores Alferov**, Physicist, Nobel Laureate, Moscow (RUS) • **Prof. Dr. Werner Arber**, Biologist and Biophysicist, Nobel Laureate, Basel (CH) • **Prof. Dr. Lajos P. Balogh**, Editor-in-Chief, Nanomedicine, Nanotechnology, Biology and Medicine, Elsevier and Member of the Executive Board, American Society for Nanomedicine, Boston (USA) • **Dr. Twan Lammers, PhD, DSc**, Experimental Molecular Imaging, RWTH Aachen, Aachen (D) • **Prof. Dr. med. Jacques André Bazex**, Member of the FANM, Toulouse (F) • **Dr. Nadia Benkirane-Jessel**, Research Director INSERM, University of Strasbourg (F) • Prof. Dr. Gerd Binnig, Founder of Definiens, Nobel Laureate • **Prof. Dr. Gerd Binnig** Founder of Definiens Inc., Nobel Laureate (D) • **Patrick Boisseau**, CEA-Leti-Minatec, Chairman of the Board of the ETPN, Grenoble (F) • **Prof. Dr. Dr. h.c. Fritz Bühler**, Coordinator, IMI PharmaTrain, Basel (CH) • **Dr. med. Victor Brantl, M.Sc.**, Head Quality Development and Pharmacovigilance, R&D Acino Pharma AG, Aesch (CH) | • **Dr. Andreas Burckhardt**, Chairman of Bâloise Group, Basel (CH) • **Dr. Peter Burckhardt**, CEO, EVA The Basel Life Sciences Start-up Agency, Basel (CH) • **Dr. Beat Butz**, Coordinator of the Swiss National Foundation, Bern (CH) • **Prof. Dr. med. Jacques Chambron**, French Academy of Sciences, Paris / Strasbourg (F) • **Prof. Dr. Edwin C. Constable**, Vice Principal and Head of Research of the University of Basel (CH) • **Dr. Michael Hehenberger**, Ph.D., CEO, HM NanoMed, Westport CT

(USA) • **Prof. Dr. med. Patrick Couvreur**, Centre d'études Pharmaceutiques (CNRS), Paris (F) • **Prof. Dr. Mike Eaton**, London (UK) • **Dr. Christoph Eymann**, Member of the Governing Council of the Canton of Basel, Basel (CH) • **Andreas Falk, MSc.**, CEO, BioNanoNet Research Association, Graz (AT) • **Prof. em. Dr. Peter Gehr**, University of Berne, President of NRP 64, Berne (CH) • **Dr. Peter Gloor**, Honorary Chairman of the Association Regio Basiliensis, Basel (CH) • **Dr. Michael Ausborn**, F. Hoffmann-La Roche Ltd., Basel (CH) • **Prof. Dr. Gerda Huber**, Director of School of Life Sciences, Muttenz (CH) • **Dr. Silke Krol**, Fondazione IRCCS Istituto Neurologico "Carlo Besta" IFOM-IEO-campus, Milan (I) • **Prof. Dr. Kostas Kostarelos, PhD, FRSM, FloN, FRSA**, Chair of Nanomedicine, Head, Centre for Drug Delivery Research Nanomedicine Lab ,UCL School of Pharmacy, University College London (UK) • **Prof. Dr. Karl J. Lackner**, President, German Association for Clinical Chemistry and Laboratory Medicine, Mainz (D) • **Prof. Dr. Jean Marie Lehn** Nobel Laureate, ISIS, Université Louis Pasteur, Strasbourg and Collège de France, Paris, Strasbourg / Paris (F) • **Prof. Dr. med. Klaus Lindpaintner**, CSO Analytical Technologies, ThermoFisher Scientific, Waltham, MA (USA) • **Prof. Dr. Stergios Logothetidis**, Aristotele University of Thessaloniki (GR) • **Prof. Dr. Witold Lojkowski**, Head of Nanostructures Laboratory, Institute of High Pressure Physics PAS, Polish Academy of Sciences, Warszawa (PL) • **Prof. Dr. med. Peter Meier-Abt**, University of Basel (CH) • **Prof. Dr. Jan Mollenhauer**, University of Southern Denmark, Head Molecular Oncology, Odense (DK) • **Prof. Dr. Hans Myhre**, Surgeon at the University Hospital, Oslo (N) • **Dr. Bernd Riebesehl**, Principal Fellow Novartis Pharma AG, Basel (CH) • **Dr. med. Dieter Scholer**, Member of the Swiss Academy of Medical Sciences, Basel (CH) • **Prof. Dr. Christian Schönenberger**, Director of the Swiss Nanoscience Institute, Basel (CH) • **Peter Schönherr**, Past Ambassador of the Netherlands, Berne (CH) • **Prof. Dr. med. Jürg Schifferli**, Head Internal Medicine, University Hospital Basel, Basel (CH) • **Prof. Dr. G. Scoles**, University Hospital of the University of Udine, Udine (I) and Temple University, Philadelphia (USA) • **Prof. Dr. Joachim Seelig**, Biozentrum, Basel (CH) • **Prof. Dr. Paul Siffert**, Secretary General, European Research & Materials Society (EMRS). Strasbourg (F) • **Dr. Frank Sinner**, Deputy Head of HEALTH - Institute of Biomedicine and Health Sciences JOANNEUM RESEARCH, Graz (AT) • **Prof. Dr. med. Janos Szebeni**, Nanomedicine Research and Education Center, Semmelweis University/Dept. Nanobiotechnology, Miskolc University and SeroScience Inc., Budapest (H) • **Prof. Dr. Donald Tomalia**, Director of the National Dendrimer & Nanotechnology Center, Central Michigan University (USA) • **Dr. med. Panagiotis Trohopoulos**, Cardiologist and Nano-Physician, Thessaloniki (GR) • **Prof. Dr. Viola Vogel**, Laboratory of Applied Mechanobiology, ETH, Zürich (CH).

University Village Country Representatives

- **Austria** **BioNanoNet Forschungsgesellschaft mbH, Graz, AUSTRIA (A)**
- **Denmark** **University of Southern Denmark, Institute of Molecular Medicine/ Molecular Oncology/ NanoCAN, Odense (DK)**
- **Germany** **BioInterfaces International Graduate School, Institute of Toxicology and Genetics KIT Campus Eggenstein – Leopoldshafen (D)**
- **Hungary** **Semmelweis / Miskolc Universities, Budapest (H)**
- **Israel** **Tel Aviv University Ramat Aviv, Tel Aviv (IL)**
- **Italy** **Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta IFOM-IEO-campus, Milano (I)**
- **The Netherlands** **University of Twente, Enschede (NL)**
- **Norway** **SINTEF (Stiftelsen for industriell og teknisk forskning), Trondheim (N)**
- **Poland** **Institute of High Pressure Physics, Polish Academy of Sciences, Warsaw (PL)**
- **Switzerland** **University Hospital Basel Swissnano-Research Group, Basel and Center for Cellular Imaging and Nanoanalytics, Biozentrum, University Basel (CH)**
- **United Kingdom** **University of Liverpool, Molecular and Clinical Pharmacology (UK)**

The Exhibitors at CLINAM 7 / 2014

TECOmedical AG, Sissach, Switzerland



CYBERNANO, Nancy, France

EVA – The Basel Start-up Agency Basel, Switzerland



EXIQON, Vedbaek, Denmark

HUBERLAB. AG, Aesch, Switzerland



IMDEA Nanociencia, Madrid, Spain

Izon Science Europe Ltd. Oxford, England



Lipoid AG, Steinhausen, Switzerland

Malvern Instruments, Herrenberg, Germany



Nanosurf AG, Liestal, Switzerland

NanoVelos Sp, Warszawa, Poland



Optofluidics, Inc., Philadelphia, PA, USA

Polymun Scientific, Klosterneuburg, Austria



SCIENION AG, Berlin, Germany

Seroscience Ltd. Budapest, Hungary



CLINAM 7/ 2014 Programme Overview Monday June 23 – Wednesday June 25, 2014

	Hall Montreal	Hall Singapore	Hall Sydney	Hall Rio	Hall MCH Lounge
Monday					
08:30	1. Opening (08:30)				
09:30	BREAK				
10:00	2. Keynote Prof. Aaron Ciechanover, Nobel Laureate				
10:50	3. Unsolved Clinical Problems & Challenges Today				
11:50	4. Keynote Prof. Gerrit Borchard				
12:25	5. Keynote Prof. Omid Farokhzad, Blend. Selecta, BIND				
13:00	LUNCH				
14:20	6. Nanomedical Interactions with and in Biological Systems	7. ETPN Session Development Europe	8. Technologies enabling Personalized Medicine	9. Innovative Tools & Materials	
16:30	BREAK				
17:00	12. Therapeutic Antibodies	10. Cost Efficiency and Socioeconomic of Future Medicine	11. Ophthalmology	9. Continuation of Session	
18:15	SHORT BREAK				
18:30	13. Rethinking the Goals of Medicine Prof. Gottfried Schatz				
19:15	End of Day 1				
19:40	Hotel Le Plaza Lobby: Leaving for Evening Event				
Tuesday					
08:00	Hall Montreal				
08:00	14. Pushing the Limits of Nano- and Targeted Medicine				
10:30	BREAK				
11:00	15. Late breaking and Ongoing Trials 1	16. ETP Brokerage and Universities Small Speeches	17. Value and Methods of Science	18. Regenerative Nanomedicine	
11:50				19. Nanomaterials Cellular Handling / Targets	
13:00	LUNCH				
14:15	20. Targeted and Personalised Cancer Nanomedicine Part 1	21. Neglected Diseases Diagnostics and Therapy	22. Toxicology in Targeted Nano-Medicine	23. Interaction Nanomedicines & Immune System	
16:30	BREAK				
17:00	24. Regulatory Authorities Session "Nanomedicine"				
19:00	End of Day 2				
19:00	Apertif / Poster Awards				
20:00	Hotel Le Plaza Lobby Leaving for Speakers Dinner				
Wednesday					
08:00	Hall Montreal	Hall Singapore	Hall Sydney	Hall Rio	Hall MCH Lounge
08:00	25. Characterization for Nanomedicine – key Methods	28. Late breaking and Ongoing Trials 2	27. Neurodegenerative Disease / Impacts of BBB	26. Nanomedicine in Cardiology	
10:00	BREAK				
10:30	32. ERC – Learning about Large funded Projects	30. Materials for Transport in Nanomedicine	29. Nanophysics	31. Targeted and Functional Nanoparticles	33./1 The international Regulators Meeting on Nanotechnology (EMA, FDA, Canada Health et al.) Closed Session
11:15	33./2 The International Regulators Follow-up Debate Open Session For members of the Summit				
12:00	LUNCH				
13:00	34. Nanomedicine and Targeted Drug Delivery The Pharmaceutical Model towards Novel Medicine, APV-session	35. Targeted and Personalized Cancer Nanomedicine Part 2	38. Pharmacokinetics & Physiology in Nanomedicine	36. Implications of Nanomedicine in the Ethical View	
14:15		39. Nanomedicine in infection		37. Diagnosis and Therapy waiting for Nanomedical Solutions	
15:15	BREAK				
15:45	40. The keyrole of Science Leading to Innovation for the Benefit of Individuals & Mankind - Dr. Frank Weichold, FDA, Prof. Dr. Werner Arber, Nobel Laureate, Dr. Christopher Anzalone Arrowhead, Pasadena Prof. Dr. Gerd Binnig, Nobel Laureate, Prof., Dr. Patrick Hunziker, University Hospital Basel				
18:10	Closing words & Announcing of CLINAM 8 / 2015				
18:15	End of Day 3				
19:00	Light Farewell Dinner for Speakers staying in Basel and Invited Guests				

The European Summit for Clinical Nanomedicine and Targeted Medicine, CLINAM 7/14


Basel, Switzerland, Monday, June 23 – Wednesday, June 25, 2014

Joint Collaborators of the CLINAM & ETPN Summit

All Joint Collaborators are non profit- organisations or governmental bodies



European Society for Nanomedicine (ESNAM), Basel (CH)



Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken (D)



EUROPEAN COMMISSION

EU, Directorate-General for Research & Innovation, (RTD) Brussels (B)



European Association for Predictive and Preventive and Personalised Medicine (EPMA), Brussels (B)



European Platform for Photodynamic Medicine's (EPPM), Hull (UK)



European Materials Research Society (E-MRS), Strasbourg (F)



BioNanoNet Research Association (BioNanoNet), Graz (A)



EURO-NanoTox – Austrian Hub for Nanosafety (EURO-NanoTox) Graz, (A)



International Association for Pharmaceutical Technology (APV), Mainz (D)

The Sponsors




Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Confederation

Federal Department of Economic Affairs,
Education and Research EAER
State Secretariat for Education,
Research and Innovation SERI



Freiwillige Akademische
Gesellschaft Basel



UNI
BASEL



EXIQON
Seek Find Verify

TECOmedical Group
always your partner



adolphe merkle institute | UNIVERSITY
OF FRIBOURG
SWITZERLAND
excellence in pure and applied nanoscience



Löffler & Associates
Concept Engineering

^b
UNIVERSITÄT
BERN



European Materials Forum



FONDS NATIONAL SUISSE
SCHWEIZERISCHER NATIONALFONDS
FONDO NAZIONALE SVIZZERO
SWISS NATIONAL SCIENCE FOUNDATION



SWISS
NANOSCIENCE
INSTITUTE



Eidgenössische Technische Hochschule Zürich
Swiss Federal Institute of Technology Zurich



H. LEIDENFROST AG • DISCOUNT PRINT
MEDIENGESTALTUNG • DIGITALDRUCK • OFFSETDRUCK • FINISHING



... and further sponsors